このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

南アフリカの思春期の少女と若い女性を HIV ワクチンの誤った情報から守る (PROTECT)

2026年8月28日 更新者:University of Pennsylvania

Adolescent girls and young women (AGYW) between the ages of 15-29 years continue to bear the brunt of Human Immunodeficiency Virus (HIV) infections in South Africa despite progress recorded in prevention and treatment programmes. The ongoing susceptibility of young women to HIV infection and the sub-optimal uptake of prevention options such as Pre-Exposure Prophylaxis (PrEP) that are highly effective creates a need for an HIV vaccine to benefit populations at substantial risk of HIV infection. However, lessons from previous vaccine studies and the recent COVID-19 vaccine have highlighted significant barriers to vaccine uptake, such as widespread misinformation and vaccine hesitancy. These challenges threaten the successful implementation of a future HIV vaccine. Building on these insights, this study will utilise psychological inoculation theory to develop and evaluate HIV vaccine messages among adolescent girls and young women. Primary objective: To compare changes in intentions to receive HIV vaccine following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.

Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about the HIV vaccine in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.

調査の概要

状態

積極的、募集していない

研究の種類

介入

入学 (実際)

2163

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Johannesburg、南アフリカ
        • Health Economics and Epidemiology Research Office, University of the Witwatersrand

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~29年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Female
  • Age 18-29 years
  • Self-reported history of sexual activity in the past 12 months
  • Self-reported HIV-negative status or unknown HIV status at enrolment
  • Willing and able to provide written informed consent
  • Able to read and understand English

Exclusion Criteria:

  • Unwilling or unable to provide consent for study participation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Control

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

他の:Enhanced inoculation message

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
HIV Vaccine Intention, at the End of the Baseline Assessment
時間枠:At the end of the baseline assessment

Intention to get the HIV vaccine, measured after inoculation intervention and misinformation exposure The intention to get the vaccine will be measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

At the end of the baseline assessment

二次結果の測定

結果測定
メジャーの説明
時間枠
HIV Vaccine Intention, Follow-up
時間枠:2-4 weeks

Intention to get the HIV vaccine, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

2-4 weeks
Recommend to Friends, at the End of the Baseline Assessment
時間枠:At the end of the baseline assessment

Intention to recommend the HIV vaccine to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

At the end of the baseline assessment
Recommend to Friends, Follow-up
時間枠:2-4 weeks

Intention to recommend the HIV vaccine to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

2-4 weeks
Credibility of Inoculated Exposure #1
時間枠:At the end of the baseline assessment

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #2
時間枠:At the end of the baseline assessment

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #3
時間枠:At the end of the baseline assessment

Extent to which claim #3 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #4
時間枠:At the end of the baseline assessment

Extent to which claim #4 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #5
時間枠:At the end of the baseline assessment

Extent to which claim #5 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #6
時間枠:At the end of the baseline assessment

Extent to which claim #6 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #1
時間枠:At the end of the baseline assessment

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #2
時間枠:At the end of the baseline assessment

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #3
時間枠:At the end of the baseline assessment

Extent to which claim #3 made the participants anxious or nervous about the HIV vaccine. TThey were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #4
時間枠:At the end of the baseline assessment

Extent to which claim #4 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #5
時間枠:At the end of the baseline assessment

Extent to which claim #5 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #6
時間枠:At the end of the baseline assessment

Extent to which claim #6 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #1
時間枠:At the end of the baseline assessment

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #7
時間枠:At the end of the baseline assessment

Extent to which claim #7 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #3
時間枠:At the end of the baseline assessment

Extent to which claim #3 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #4
時間枠:At the end of the baseline assessment

Extent to which claim #4 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #5
時間枠:At the end of the baseline assessment

Extent to which claim #5 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #6
時間枠:At the end of the baseline assessment

Extent to which claim #6 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #1, Follow-up
時間枠:2-4 weeks

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of Inoculated Exposure #2, Follow-up
時間枠:2-4 weeks

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Shareability of Inoculated Exposure #1, Follow-up
時間枠:2-4 weeks

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of Inoculated Exposure #2, Follow-up
時間枠:2-4 weeks

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Anxiousness of Inoculated Exposure #1, Follow-up
時間枠:2-4 weeks

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of Inoculated Exposure #2, Follow-up
時間枠:2-4 weeks

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Credibility of New Claims, Exposure #12, Follow-up
時間枠:2-4 weeks

Extent to which claim #12 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #8, Follow-up
時間枠:2-4 weeks

Extent to which claim #8 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #9, Follow-up
時間枠:2-4 weeks

Extent to which claim #9 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #10, Follow-up
時間枠:2-4 weeks

Extent to which claim #10 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #11, Follow-up
時間枠:2-4 weeks

Extent to which claim #11 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness o of New Claims, Exposure #12, Follow-up
時間枠:2-4 weeks

Extent to which claim #12 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Claim #8, Follow-up
時間枠:2-4 weeks

Extent to which claim #8 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #9, Follow-up
時間枠:2-4 weeks

Extent to which claim #9 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #10, Follow-up
時間枠:2-4 weeks

Extent to which claim #10 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #11, Follow-up
時間枠:2-4 weeks

Extent to which claim #11 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #12, Follow-up
時間枠:2-4 weeks

Extent to which claim #12 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #8, Follow-up
時間枠:2-4 weeks

Extent to which claim #8 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #9, Follow-up
時間枠:2-4 weeks

Extent to which claim #9 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #10, Follow-up
時間枠:2-4 weeks

Extent to which claim #10 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #11, Follow-up
時間枠:2-4 weeks

Extent to which claim #11 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Credibility of Inoculated Exposure #7
時間枠:At the end of the baseline assessment

Extent to which claim #7 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #7
時間枠:At the end of the baseline assessment

Extent to which claim #7 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #2
時間枠:At the end of the baseline assessment

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of New Claims, Exposure #13, Follow-up
時間枠:2-4 weeks

Extent to which claim #13 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness of New Claims, Exposure #13, Follow-up
時間枠:2-4 weeks

Extent to which claim #13 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #13, Follow-up
時間枠:2-4 weeks

Extent to which claim #13 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年7月24日

一次修了 (実際)

2025年10月16日

研究の完了 (推定)

2027年6月1日

試験登録日

最初に提出

2024年11月7日

QC基準を満たした最初の提出物

2024年11月18日

最初の投稿 (実際)

2024年11月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年8月28日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 1R01MH132401 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

The investigators are still determining the data sharing plan and if we will be sharing IPD yet

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する